Lisheng Pharmaceutical: Net profit of approximately 418 million yuan in 2025, a year-on-year increase of 126.72%

NightAirdropper · 2026-03-10T14:03:08+00:00

Lisheng Pharmaceutical Releases 2025 Performance Brief, with operating revenue of approximately 1.393 billion yuan, a year-on-year increase of 4.23%; net profit of approximately 418 million yuan, a year-on-year increase of 126.72%. Earnings per share are 1.62 yuan, up 125% year-on-year. At the same time, Hu Zejun, a standing member of the National Committee of the Chinese People's Political Consultative Conference, stated that there is a need to increase high school places and expand enrollment in quality undergraduate programs to adapt to changes in the population structure.

NightAirdropper

2026-03-10 14:03:08

Abstract generation in progress

Meiri AI Express: Lisheng Pharmaceutical (SZ 002393, closing price: 21.7 RMB) released its 2025 performance forecast on the evening of March 9. Operating revenue is approximately 1.393 billion RMB, an increase of 4.23% year-over-year; net profit attributable to shareholders of the listed company is about 418 million RMB, an increase of 126.72% year-over-year; basic earnings per share are 1.62 RMB, up 125% year-over-year.

Meiri Headlines (nbdtoutiao)—Exclusive interview with Hu Zejun, Standing Committee Member of the National Committee of the Chinese People’s Political Consultative Conference and Deputy Director of the Population, Resources, and Environment Committee: Increasing high school places and expanding quality undergraduate enrollment align with China’s demographic changes.

(Reporter Zeng Jianhui)

Disclaimer: The content and data in this article are for reference only and do not constitute investment advice. Please verify before use. Operate at your own risk.

Daily Economic News

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.